СХЕМЫ АНТИХЕЛИКОБАКТЕРНОЙ ТЕРАПИИ БОЛЬНЫХ ХРОНИЧЕСКИМИ ГАСТРОДУОДЕНАЛЬНЫМИ ЗАБОЛЕВАНИЯМИ И САХАРНЫМ ДИАБЕТОМ II ТИПА

The paper presents the analysis of effectiveness of different modifications of the triple and combinatorial anti-Helicobacter pylori (H. pylori) therapy and their in-fluence on the small intestinal overgrowth syndrome (SIBOS) in type 2 diabetic patients with chronic gastroduodenal disorders (CGDD). The open comparative randomized study included 138 diabetic patients with CGDD. Methods: Gastro-duodenal - longpathology was confirmed by gastroduodenos-copy with biopsy, H. pylori contamination - by use of the urease and citological method or finding bacterial antigen in excrements. The SIBOS was recognized by a respiratory hydrogen method with lactulose. Results: Depending on the type of anti-H. pylori regimen all patients were divid-ed into 4 groups. The less effective were found to be the 10-days-long triple ther-apy with Omeprazol (eradication in 68,7%) and the 14-days-long optimized reg-imen with Rabeprazol (80,6%of eradication). Addition of both vismuth and pro-biotic resulted in increased eradication up to 94,1% (triple intensified optimized therapy), while the optimized triple regimen with metronidazol and probiotic (in-tensified concomitant therapy) proved to be the most effective (97,2%) in H. pylori eradication. The all 4 regimens of anti- H. pylori therapy resulted in de-creased number of SIBOS cases, but the best results were obtained in patients who were on the triple intensified optimized and intensified concomitant therapy - up to 60 and 78,3% correspondingly. The positive influence of an anti-H. pylori therapy on SIBOS seen in the study allows the authors to consider SIBOS as an additional indication for an anti-H. pylori therapy.